Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABOSTO:MCAP +0.75%96 Graham Number is kr71.88 as of Jun. 2026. GuruFocus rates OSTO:MCAP with a GF Score™ of 96/100 and a GF Value™ of kr576.67 (Fairly Valued). Among 408 Medical Devices & Instruments companies, MedCap AB ranks worse than 92.89% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-09-22), the stock price of MedCap AB is kr533.50. MedCap AB's graham number for the quarter that ended in Jun. 2026 was kr71.88. Therefore, MedCap AB's Price to Graham Number ratio for today is 7.42.
The historical rank and industry rank for MedCap AB's Graham Number or its related term are showing as below:
OSTO:MCAP'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.65 Med: 4.61 Max: 47.93
Current: 6.86
During the past 13 years, the highest Price to Graham Number ratio of MedCap AB was 47.93. The lowest was 2.65. And the median was 4.61.
OSTO:MCAP's Price-to-Graham-Number is ranked worse than 92.89% of 408
companies
in the Medical Devices & Instruments industry
Industry Median: 1.845
vs OSTO:MCAP: 6.86
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
MedCap AB's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Jun. 2026 )
=
533.50
/
71.88
=
7.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
MedCap AB Graham Number Related Terms
MedCap AB Graham Number Historical Data
* Premium members only.
The historical data trend for MedCap AB's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MCAP vs ABT, SYK, MDT: Graham Number Comparison
For the Medical Devices subindustry, MedCap AB's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB Price-to-Graham-Number vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where MedCap AB's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedCap AB (OSTO:MCAP) has a Graham Number of kr71.88 as of Jun. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on MedCap AB and its competitors. According to the industry distribution chart, MedCap AB ranks #379 out of 408 companies in the Medical Devices & Instruments industry, placing it in the top 92.9%.
Is MedCap AB's Graham Number too high?
MedCap AB's current Graham Number is kr71.88. Based on the distribution chart, MedCap AB ranks #379 out of 408 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, MedCap AB has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's Graham Number compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #379 out of 408 companies for Graham Number. This places MedCap AB in the lower half of its industry. The industry median Graham Number is 1.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Medical Devices & Instruments company?
The median Graham Number among Medical Devices & Instruments companies is 1.85, based on 408 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on MedCap AB and its competitors. For the Medical Devices & Instruments industry, the median Graham Number is 1.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current Graham Number is kr71.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (OSTO:MCAP) is currently considered Fairly Valued. The stock's GF Value™ is kr576.67, compared to a current price of kr533.50 — trading 7.5% below its estimated fair value. The current Graham Number is kr71.88. MedCap AB's overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For MedCap AB (OSTO:MCAP), the current Graham Number is kr71.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (OSTO:MCAP) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of kr533.50 is trading 7.5% below its estimated GF Value™ of kr576.67.
GuruFocus considers MedCap AB to be Fairly Valued.
Key valuation signals for OSTO:MCAP:
Graham Number: kr71.88
GF Value™: kr576.67 vs. price of kr533.50 (7.5% below fair value)
No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB is a Swedish investment company that acquires and develops profitable, market-leading niche businesses in the Nordic life science sector. It operates through two business areas: Medical Technology and Specialist Medicines. The Medical Technology segment develops and sells medical technology products and services, while the Specialist Medicines segment develops and sells pharmaceuticals across the regulatory classes of registered, extemporaneous, and licensed medicines. Its subsidiaries serve healthcare providers, clinics, pharmacies, and patients, primarily in Sweden and other Nordic markets. MedCap generally takes controlling or significant ownership stakes in its portfolio companies and supports their long-term growth, often holding investments for extended periods. Revenue is generated through the consolidated sales of its operating subsidiaries rather than through a single product line, giving the company diversified exposure across medical devices, services, and pharmaceutical distribution and development within the Nordic life science industry.
96GF Score
Get the complete analysis for OSTO:MCAP
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MCAP has been successfully added to your 
